Latest kidney cancer news
ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer
Results from the phase 3 CLEAR studywere presented at the [...]
COVID-19 vaccines, boosters and immunity webinar
The National Core Studies Immunity (NCSi) Programme and UK Coronavirus Immunology Consortium (UK-CIC) are [...]
ESMO 2022: Atezolizumab as an adjuvant therapy
The results from the IMmotion010 study were presented at the [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Northern Soul fundraising event
The second Northern Soul event took place over the weekend [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo kidney cancer sunitinib cabozantinib Sutent progression-free survival NHS England biomarkers ipilimumab pembrolizumab Cabometyx axitinib COVID-19 cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus risk factors Yervoy adjuvant therapy Keytruda targeted therapy metastases papillary RCC everolimus biological markers ASCO Afinitor cancer outcomes first-line treatment NICEArchives
- 2025: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
